MV Capital Management’s Royalty Pharma RPRX Stock Holding History

MV Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$7.24K	Hold	124	–	–	﹤0.01%	597
2026 Q2	$6.95K	Buy	124 +19	+18%	+$989	﹤0.01%	593
2026 Q1	$5.04K	Buy	105 +1	+1%	+$44	﹤0.01%	619
2025 Q4	$4.02K	Hold	104	–	–	﹤0.01%	637
2025 Q3	$3.67K	Hold	104	–	–	﹤0.01%	639
2025 Q2	$3.75K	Buy	104 +47	+82%	+$1.56K	﹤0.01%	636
2025 Q1	$1.78K	Buy	57 +18	+46%	+$571	﹤0.01%	707
2024 Q4	$995	Buy	39 +27	+225%	+$716	﹤0.01%	751
2024 Q3	$340	Sell	12 -1	-8%	-$28	﹤0.01%	848
2024 Q2	$343	Buy	13 +8	+160%	+$222	﹤0.01%	757
2024 Q1	$152	Buy	5 +3	+150%	+$88	﹤0.01%	743
2023 Q4	$57	Buy	+2	New	+$55	﹤0.01%	746

Other funds holding RPRX

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $127B AUM 33.25% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

New South Capital Management Memphis, Tennessee $1.53B AUM 36.31% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

MV Capital Management's RPRX Position: Q3 2026 in Review

MV Capital Management held its Royalty Pharma (RPRX) position steady in Q3 2026 at 124 shares worth $7.24K. The position accounts for ﹤0.01% of the portfolio, ranked #597.

MV Capital Management first reported a position in RPRX in Q4 2023 and has held it in 12 quarters since. 326 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

MV Capital Management held 124 shares of Royalty Pharma worth $7.24K as of Q3 2026.
MV Capital Management left its Royalty Pharma share count unchanged in Q3 2026.
Royalty Pharma made up ﹤0.01% of MV Capital Management's portfolio in Q3 2026, its #597 holding.
MV Capital Management first reported a position in Royalty Pharma in Q4 2023 and has held it in 12 quarters since.
326 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on MV Capital Management's 13F filing for Q3 2026, filed 29 Oct 2026.